Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Annals of Surgical Oncology|February 25, 2026
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 StudySherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
JAMA Network Open|June 1, 2026
Digital Self-Management of Symptoms and Quality of Life for Patients With Advanced Cancer: A Randomized Clinical TrialWing-Lok Chan, Inda Sung Soong, Mei-Ying Lim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2021
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
The Lancet. Oncology|February 16, 2019
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trialSherene Loi, Anita Giobbie-Hurder, Andrea Gombos, et al.
The New England Journal of Medicine|February 27, 2020
Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Lajos Pusztai, et al.
The Lancet. Oncology|February 10, 2020
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialMarina C Garassino, Shirish Gadgeel, Emilio Esteban, et al.
The Annals of Thoracic Surgery|November 7, 2025
Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671Moishe Liberman, David R Jones, Heather Wakelee, et al.
Investigational New Drugs|November 10, 2025
A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitorsHoi Wai Chan, Chris Chun Long Tse, Yu-Chung Li, et al.
JTO Clinical and Research Reports|February 16, 2023
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLCMarina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2025
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 StudyRoy S Herbst, Byoung Chul Cho, Caicun Zhou, et al.
Pageof 9